Humanity's Future - Centuries, Millenia and Beyond
The ever-accelerating pace of technological innovation makes the long-term future difficult to visualise. It’s important, when thinking in the long term, to understand that different problems will require different solutions. Interstellar travel and building habitats in space may help us survive the next billion years, but these technologies will not arrive in time to allow us to live out the century. If we want to be sure we will be around to tackle major problems, we’ll need to get a lot better at thinking beyond the next five years.
The Patient Orator® solution is designed to break down barriers making it difficult for patients to communicate with healthcare providers and improve access to basic health care resources. The approach is collaborative. The patient, caregivers, their social support team/care management team, and medical providers focus on hearing the voice of the patient to help them in their health and wellness journey.You can subscribe to be notified of the app release www.patientorator.com
Researchers at The University of Queensland will progress toward a trial to see if a specialised dietary fibre supplement is safe for use in children with type 1 diabetes after positive results in adults. With the increase of type I diabetes in the last 50 years, growing evidence is showing that changes in gut bacteria may hold a secret to the triggering of the disease. By targeting the gut microbiome with specialised dietary fibre supplements, researchers hope to see a low-cost approach to prevention and glucose management. | https://medicine.uq.edu.au/article/2021/07/diabetes-research-challenging-paramount
Researchers at the University of Queensland and WEHI have identified a new generation anti-cancer drug that could be repurposed for aggressive childhood brain tumour, medulloblastoma. The international collaboration spent five years mapping the genetics of this common and fatal brain cancer for children. The existing drug has been approved for other diseases or cancers but never tested in paediatric brain tumours. Ixabepilone which is used to treat breast cancer, was found to block tumour growth and significantly extend survival rates in preclinical models. | https://www.uq.edu.au/news/node/129501